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Background: Endothelial progenitor cells (EPCs) play a fundamental role in post-natal vascular repair. Currently
EPCs are defined as either early and late EPCs based on their biological properties and their time of appearance
during in vitro culture. EPCs are rare and therefore optimizing isolation and culture is required before they can be
applied as part of clinical therapies.
Results: We compared the gene profiles of early/late EPCs to their ancestors CD133+ or CD34+ stem cells and to
matured endothelial cells pinpointing novel biomarkers and stemness genes. Late EPCs were enriched with
proliferation and angiogenesis genes, participating in endothelial tubulogenesis and hence neovascularization. Early
EPCs expressed abundant inflammatory cytokines and paracrine angiogenic factors, thereby promoting
angiogenesis in a paracrine manner. Transcription factors involved in EPC stemness were pinpointed in early EPCs
(MAF/MAFB) and in late EPCs (GATA6/IRF6).
Conclusions: The detailed mRNA expression profiles and functional module analysis for different EPCs will help the
development of novel therapeutic modalities targeting cardiovascular disease, tumor angiogenesis and various
ischemia-related diseases.Background
Defects in angiogenesis (blood vessel growth) or in vessel
repair are major complications in many diseases, such
as diabetes, atherosclerosis and myocardial infarction.
Post-natal neoangiogenesis relies largely on circulating
endothelial progenitor cells (EPCs) [1]. The regulation
of angiogenesis depends not only on the number of circu-
lating EPC but also on their activities [1]. Current EPC
definitions are based predominantly on phenotypes and
biological properties. Early EPCs (eEPCs) appear early
(<1 weeks) in culture dishes, whereas late EPCs appear
late (2–4 weeks) and have a cobblestone-like morphology
[2]. Strikingly different angiogenic properties between
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reproduction in any medium, provided the orangiogenesis assay: late-outgrowth EPCs but not eEPCs
form vascular networks de novo, while late EPCs but not
eEPCs are incorporated into vascular networks [3]. By way
of contrast, eEPCs, but not late EPCs, indirectly augment
tubulogenesis even when physically separated by a
Transwell membrane, which implies that the effect is via a
paracrine mechanism [3-5].
Given their involvement in pathological and physio-
logical angiogenesis, there has been growing interest in
understanding and manipulating EPCs for therapeutic
purposes. Detailed molecular analysis of EPCs before and
during endothelial differentiation is still lacking. Since
there is no direct differentiation system available for
obtaining EPCs from CD133+ stem cells (hemangioblasts),
the post-natal endothelial stem cells, genomics data so far
has relied on a purified subpopulation (“static”) approach.
Microarray analysis has been performed on freshly iso-
lated (day 0) human cord blood-derived endothelial
progenitors (CD133 + KDR + or CD34 + KDR+), and at
different time points during in vitro differentiationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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has been possible to identify molecular targets crucial
for EPC differentiation and stemness and to test their
involvement in EPC function. For example, in a follow-
up study, the Notch signaling pathway was found to
regulate EPC pro-angiogenic or pro-wound healing
properties [7]. Recent research has applied microarray
and proteomics approaches to unmask the mRNA and pro-
tein compositions of eEPC and late EPC [8]. Re-analyzing
and organizing array data using an advanced systems
biology approaches to better understand EPC biology
will improve significantly our understanding of EPC
biology.
In this study we aim to better define the roles of early
and late EPCs in angiogenesis, as well as to explore
some of the underlying mechanisms. AC133+/CD133+
hemangioblasts, CD34+ angioblast precursors and ter-
minal differentiated matured ECs were included as refer-
ence cell types.
Methods
Isolation and cultivation of EPCs from cord blood
Fresh human cord blood was obtained from pregnant
female volunteers aged 25–35, without significant disease,
not receiving any medication and without any clinical
diagnosis. All patients gave informed consent, and the
study was approved by the local research ethics commit-
tee. The protocols of this study were consistent with
ethical guidelines provided in the 1975 Helsinki Decla-
ration. EPC isolation and characterization were done as
described with minor modifications [9,10]. Cord blood
mononuclear cells (MNCs) isolated by Histopaque-1077
(1.077 g/ml, Sigma, St. Louis, Missouri, USA) density-
gradient centrifugation to minimize cellular blood compo-
nents such as platelets. 1 × 107 mononuclear cells (MNCs)
were plated in 2 ml endothelial growth medium-2 (Lonza
Ltd., Basel, Switzerland), with supplementation (hydrocor-
tisone, IGF-1, human EGF, human VEGF, human FGF-B,
ascorbic acid, GA-1000, heparin and 2% fetal bovine
serum) in a fibronectin-coated well of a 6-well plate. After
3–5 days of 5% CO2, 37°C cultivation, attached eEPCs
appeared and medium and nonadherent cells were then
removed. Medium were changed every two days, and
colonies of late EPCs (lEPCs) appeared after 2–3 weeks.
The late EPCs exhibited “cobblestone” morphology and a
monolayer growth pattern that is typical of mature endo-
thelial cells at confluence. Thereafter, lEPC colonies
were trypsinized and cultured on fibronectin pre-coated
(5 μg/cm2, Millipore) wells or plates (2 × 104/cm2) for
further experiments.
EPC characterization and tube formation assay
The antibodies used in FACS to characterize the adhe-
rent cell population were CD34 (BD Pharmingen,Franklin Lakes, NJ USA), kinase insert domain receptor
(KDR)/VEGF receptor 2 (R&D system, Minneapolis, MN
USA), VE-cadherin (AbD Serotec, Kidlington, UK),
AC133 (CD133), platelet–endothelial cell adhesion
molecule-1 (CD31; Miltenyi Biotech GmBH, Bergisch
Gladbach, Germany) and CD45 (Biolegend, San Diego,
CA USA). Flow cytometry was performed using a
FACSCanto flow cytometer (BD Pharmingen, Franklin
Lakes, NJ USA).
The in vitro tube formation assay was performed by
thawing Matrigel at 4°C overnight, and then placed it in
a 96-well plate at 37°C for 1 h to allow the matrix solu-
tion to solidify. EPCs were harvested with trypsin/EDTA,
and 1 × 104 EPCs were placed on Matrigel with EGM-2
medium or serum-free DMEM and incubated at 37°C
for 6 h. Tubule formation was inspected under an
inverted light microscope (100×). Four representative
fields were taken.
For 3D angiogenesis assay, collagen type I acidic solution
were mixed with 1/2 volume of basic conditioned medium
with 0.2 ug/ml SDF-1α (R&D system, Minneapolis, MN
USA) and solidify 30 minutes in 96-well plate at 37°C in a
5% CO2 incubator. 10
5 cells per well were seeded and
assayed.
Gene expression microarray
CD133+ stem cells and CD34+ precursor, blood vessel
endothelial cells (BEC), lymphatic endothelial cells
(LEC) and PBMCs array data were from our previous
publication [11]. GEO microarray datasets (http://www.
ncbi.nlm.nih.gov/geo/) included in this study were
GSE12891 [12] and GSE10856 [13] (the sources of the
microarray data were summarized in Additional file 1:
Table S1). Total RNA sample preparation, cRNA probe
preparation, array hybridization and data analysis were
done as described previously [14]. AffymetrixTM HG-
U133 Plus 2.0 whole genome chips were used. Batch
effects were minimized by the sva (Surrogate Variable
Analysis) package of the Bioconductor suite (http://
www.bioconductor.org) for the R statistical program-
ming language (http://www.r-project.org). RMA log
expression units were calculated from Affymetrix
GeneChip array data using the ‘affy’ package of the
Bioconductor suite. The default RMA settings were used
to background correct, normalize and summarize all
expression values. Significant differences between the
sample groups was identified using the ‘limma’ (Linear
Models for Microarray Analysis) package of the
Bioconductor suite, and an empirical Bayesian moder-
ated t-statistic hypothesis test between the two specified
phenotypic groups was performed [15]. To control for
multiple testing errors, we then applied a false discov-
ery rate algorithm to these p values in order to calcu-
late a set of q values, thresholds of the expected
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null hypothesis [16].
Heat maps were created by the dChip software (http://
www.dchip.org/). Principal component analysis (PCA)
was performed by the Partek Genomics Suite (http://
www.partek.com/) to provide a visual impression of how
the various sample groups are related. Gene annotation
was performed by our ArrayFusion web tool (http://micro-
array.ym.edu.tw/tools/arrayfusion/) [17]. Gene Ontology
database search were performed by the DAVID 6.7 Bio-
informatics Resources (http://david.abcc.ncifcrf.gov/). The
Euclidean distance between two groups of samples is
calculated by the average linkage measure (the mean of
all pair-wise distances (linkages) between members of
the two groups concerned) [14]. The standard error of
the average linkage distance between two groups (the
standard deviation of pair-wise linkages divided by the
square root of the number of linkages) is quoted whenFigure 1 Cultivation and characterization of early and late EPCs. (A) E
(B) Late EPCs and matured ECs, but not early EPCs, formed tubules in vitro.
late EPCs and matured ECs formed vessel structures in 3D-angiogenesis assinter-group distances are compared in the text. Differ-
ential gene expression profiles were imported into the
Ingenuity Pathways Analysis (IPA) software (Ingenuity
Systems, Redwood City, CA, USA; http://www.ingenuity.
com/) to compare the biological activities of different
cell types.
Results
Isolation and characterization of human endothelial
precursor cells
EPCs were obtained from the cord blood of healthy sub-
jects as described [10]. The peripheral blood MNCs that
were initially seeded on fibronectin-coated wells were
round. After changing the medium on day 4, attached
eEPCs with an elongated morphology appeared. Late
EPCs with a cobblestone-like morphology similar to
mature endothelial cells grew to confluence at days 14–21.
The expression of cell lineage markers on the differentxpression of indicated molecules in EPCs by flow cytometric analysis.
Representative photos for in vitro angiogenesis are shown. (C) Both
ays. Bar = 200 um.
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try analysis. The majority of cells that were late EPCs and
HUVECs expressed CD31, and KDR endothelial markers,
while hematological marker CD45 was present on eEPCsFigure 2 Distinct gene expression patterns in endothelial cells of diff
analysis (PCA) plot using genes differentially expressed between CD133+ st
GSE12891: early and late EPCs from GEO data set GSE12891. Each spot repr
each endothelial lineage cell type. Columns represent human tissue and st
increased expression; in blue: decreased. (C-D) Cell membrane proteins spe
“Cellular Component” ontology in the GO database. (E-F) Mean gene expre
GAPDH control; n = 3). Results are expressed as the mean ± standard devia(Figure 1A). In contrast, CD31 and KDR were present on
only part of the isolated eEPC population (Figure 1A). An
in vitro tube formation assay was performed using the
isolated EPCs to characterize their functionality beforeerent postnatal differentiation stages. (A) A principal component
em cells and matured endothelial cells (8880 probe sets, q < 10-4).
esents a single array sample. (B) A heat map showing genes unique in
em cell samples, while rows represent probe sets. Genes in red:
cifically expressed in early (C) or late (D) EPCs according to the
ssion levels of early (E) or late (F) EPC surface proteins (compared to
tion. ND: not detectable. *: P < 0.05 by analysis of variance (ANOVA).
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HUVEC and late EPCs formed tubule networks on
Matrigel, while eEPC were not able to do this (Figure 1B).
Late EPCs also formed capillary-like structures in a 3D
angiogenesis assay (Figure 1C).
Microarray analysis reveals novel biomarkers for early
and late EPCs
Post-natal endothelial differentiation is considered to
start with the AC133+/CD133+ hemangioblast stem cell
population, followed by CD34+ stem/precursor cells,
EPCs, and finally mature endothelial cells [11]. To access
the molecular mechanisms governing the diverse behav-
iors of the different EPCs, as well as to help elucidate
the somatic endothelial differentiation mechanisms, we
analyzed EPC transcriptome profiles using whole
genome chips and then compared them to those of
other endothelial lineage cells obtained by our group
[11]. A PCA plot using genes differentially expressed
between CD133+ ancestor stem cells and matured endo-
thelial progeny cells (n = 8880, positive false discovery
rate (pFDR) q < 10-4) represents the differentiation hier-
archical relationship (Figure 2A). PCA derived from all
of the genes also showed a same conclusion (Additional
file 2: Figure S1).
Some of the above 8880 genes may co-present in 2 or
several cell types. To further narrow down cell type-
specific genes, we filtered only genes unique (i.e., higher
than in all other cell types) in each cell type. A total of 737
probe sets were found to be unique to eEPCs (q < 0.0001),
665 were unique to late EPCs (q < 0.0001), 318 were
unique to CD133+ stem cells (q < 0.0001), and finally
another 472 were unique to CD34+ precursors (q < 0.05).
A gene expression heat map for these genes indicates the
unique expression patterns present within each cell type
(Figure 2B). In silico data was further verified by RT-qPCR.
We focused first on membrane proteins in order to identify
novel surface markers for early and late EPCs. CD204,
CD169, GPNMB and many other membrane proteins were
uniquely expressed on eEPCs (Figures 2C & 2E), while
genes such as CXADR, OSAP and CD106 were uniquely
expressed on late EPCs (Figures 2D & 2F).
Coordinated changes in the functional groups between
different EPCs
The above gene list gave us a primary insight into the
unique composition of differential EPCs but reveals little
on EPC functions. To understand more how the gene
expression profiles might correlate with EPC biology
and to provide quantitative evidence, signature probe
sets were subjected to a Gene Ontology (GO) database
search to find statistically over-represented functional
groups within these genes. Given that the whole human
transcriptome was represented by the microarrayanalysis, this analysis was not biased toward the coverage
of the microarray. The GO categories of the biological
processes being statistically overrepresented (p < 0.05)
among the 737 eEPC-enriched probe sets are presented
in Figure 3A. The most significant biological process for
eEPCs is the inflammatory response (39 genes, p = 3.06 ×
10-13; Figure 3A, underlined). Cytokine production is also
significantly higher in eEPCs (7 genes, p = 0.00229
Figure 3A). Other related predominant processes include
those pertaining to chemotaxis (18 genes, p = 4.98 × 10-6),
regulation of responses to external stimuli (11 genes,
p = 0.0192) and positive regulation of defense re-
sponses (10 genes, p = 2.79 × 10-4) (Figure 3A).
In contrast, in late EPCs the most important biological
processes are heart and vascular development (18 and 14
genes respectively, p = 8.05*10e-4 and 0.018; Figure 3B).
BMP2, JMJD6, TGFB3, GLMN, EPAS1, and VEGFR1 all
fall within these two areas. Genes involved in cell prolifer-
ation, cell adhesion and motility are also enriched in late
EPCs (Figure 3B), corresponding to the motile and ampli-
fying nature of late EPCs. Late EPCs are also enriched
with Wnt signaling pathway genes according to the KEGG
database (p = 0.018; Additional file 3: Figure S2).
The basic functional differences between endothelial
lineage cells were further elucidated by comparing their
gene profiles side-by-side using another function explor-
ation tool, Ingenuity Pathway Analysis (IPA). Consistent
with the GO analyses above, all cell types except eEPCs
expressed significant numbers of genes involved in cardiovas-
cular system development and function (Additional file 4:
Figure S3A). Early EPCs express many more genes involved
in the humoral immune response, hematological system
development and function, and the inflammatory re-
sponse (Additional file 4: Figure S3B-C). Canonical
pathways related to innate immunity, including cyto-
kine (such as GM-CSF and IL10) signaling, TREM1 or
the toll-like receptor signaling pathway, are also specif-
ically active in eEPCs (Additional file 4: Figure S3B-C).
Early EPCs also expressed genes involved in immunity-
related diseases such as systemic lupus erythematosus
(SLE) and rheumatoid arthritis (RA) (Additional file 4:
Figure S3C). These findings indicate that late EPCs are
an attractive cell candidate for amplification in vitro
and in vivo in order to induce therapeutic angiogenesis,
while eEPCs should be used with caution because of
their possible relationships with autoimmunity disease
and allograft rejection.
Indirect contribution of eEPCs to angiogenesis and the
involvement of pro-angiogenic factors
The cytokine production and inflammatory nature of
eEPCs raised a possibility that these cells contribute to
angiogenesis indirectly by secreting angiogenic factors
and inflammatory cytokines that aid the destruction of
Figure 3 (See legend on next page.)
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Figure 3 Unique biological functions of different EPCs. The 737 and 665 early (A) and late (B) EPC genes were subjected to a Gene Ontology
(GO) database search. These categories were selected from the “Biological Process” organizing principle in the GO database (http://www.
geneontology.org/). The number of genes, gene symbols, and p values for each category that are significantly enriched are listed (p < 0.05).
Underlined: discussed in the text. (C) Culture supernatant of early EPCs increases angiogenesis ability of late EPCs in 3D-angiogenesis assays.
(D) Paracine factors uniquely expressed in early EPCs. (E) Validation of array data by real-time RT-PCR (n = 3). *: P < 0.05 by analysis of
variance (ANOVA).
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and to extend. It has been suggested that eEPCs assist
HUVEC angiogenesis via an indirect paracrine manner
[3-5]. We tested this hypothesis using a 3D-angiogenesis
assay in which the chemotaxis potential of eEPC condi-
tional medium (CM) was evaluated. As shown in
Figure 3C, conditional medium (CM) from eEPCs in-
duced better late EPC invasion than did the control
medium. We can summarize the secretome pattern of
eEPCs and this shows that eEPCs express a range of
secreted factors including HGF, IL10, IGF1, CCL3,
CCL4, CCL18, CXCL12, CXCL16 and IGF1 (Figure 3D).
The abundant expression of these factors was verified by
qPCR (Figure 3E). It has been reported that eEPCs also
express various angiogenic factors, including VEGF, IL2,
IL8, G-CSF and GM-CSF [18,19]. These factors were not
included in our list because their expression is also
abundant in other endothelial lineage cells (not shown).Unique transcription factors in EPCs
One of the main problems faced when applying EPCs
clinically is that there is not yet an optimal culturing
system that amplifies these cells in vitro for a long time
while still maintains their precursor status. In general,
late EPCs differentiate during culturing and become sen-
escent at around passage 15 (P15). From early passages
(P2-3) to late passages (P7-8), we have observed a sig-
nificant drop in CD34(+) cell numbers in late EPC popu-
lation, while the percentage of VE-cadherin(+) cells is
increased (Figure 4A & Additional file 5: Figure S4). To
understand more about how EPC identity and stemness
is maintained, we next explored the key transcription
factors in each cell type. Of note, the key stemness tran-
scription factors we filtered out may be different from
those based on embryonic stem cell studies since the
transcriptome changes during embryonic endothelial dif-
ferentiation (orange arrow, Figure 4B) are quite different
from that those of post-natal CD133+ stem cell differen-
tiation (blue arrow, Figure 4B; PCA were performed using
genes differentially expressed between ESC and matured
endothelial cell). PCA derived from all of the genes also
showed the same conclusion (Additional file 6: Figure S5).
Under such circumstances, post-natal angiogenesis and
embryonic angiogenesis should therefore, at least in part,
be controlled by different regulation systems.In eEPCs, a total of 18 nuclear transcription factors
were found from array data (Figure 4C). The unique ex-
pression of two MAF family members, MAF and MAFB,
was confirmed by qPCR (Figure 4D). Also unique to
eEPCs are RB1, CEBPD and MYCL1 (Figure 4D). On
the other hand, twelve transcription factors, including
MKL2, IRF6, GATA6 and RUNX1T1, are more abun-
dant in late EPCs (Figures 4E-F). In addition, the levels
of GATA6, GRHL1 and ETV1, TAF5L, IRF6 and MKL2
dropped dramatically during the passage of late EPCs
(Figure 4G), implying crucial roles in maintenance of
late EPC identity.
Discussion
EPCs play an important role in post-natal vascular repair
and the maintenance of vascular homeostasis through
re-endothelialization and neovascularization. The num-
ber of circulating EPCs in patient peripheral blood (PB)
inversely correlates with disease prognosis, such as dia-
betes and cardiovascular disease (CAD) [1,20,21]. CD34,
KDR, and CD133+ are considered critical markers for
the outgrowth of endothelial cell–producing late EPCs,
which are different from hematopoietic progenitors or
leukocytes. Combinations of markers, including CD133 +
CD34 + KDR+, CD34 + KDR+, or CD14 + CD34low, are
widely used to define or select cells that express properties
attributed to EPCs [22]. This approach, however, does
not consider all the characteristics of EPCs and cannot
distinguish eEPCs from late ones. Although CD34 +
VEGFR-2 + AC133+ cells are widely accepted to repre-
sent ‘true EPCs’ in humans [23], they have never been
proved to differentiate into ECs in vivo [22,23]. More-
over, recent studies show that mobilized adult periph-
eral blood CD34 + VEGFR-2 + AC133+ cells in fact
represent an enriched population of CD45+ haemato-
poietic precursors, which do not differentiate to ECs
in vitro [24]. The lack of known surface biomarkers for
the different EPCs and the absence of a standardized
protocol with regards to reagents and gating strategies
may account for the widespread inter-laboratory varia-
tions in the quantification of EPC.
Another approach to quantification is to use defined
culturing assays to culture both early and late EPCs and
then to count colony numbers. In a model of hind limb
ischaemia, late EPCs enhanced revascularization in syn-
ergy with early EPCs [4]. This strategy is also handicapped
Figure 4 (See legend on next page.)
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Figure 4 Transcription factors enriched in the various EPCs. (A) FACS data of late EPC surface antigens at different passages. (B) A principal
component analysis (PCA) plot showing distinct differentiation pathways between embryonic and somatic endothelial differentiation (using
genes differentially expressed between ESC and matured endothelial cells; 6446 probe sets, q < 10-5). ESC and differentiated precursors from the
GEO data sets GSE19735 and GSE21668. Each spot represents a single array sample. (C & E) Nuclear proteins of early (C) and late (E) EPCs (defined
by the “Cellular Component” ontology in the GO database) with transcription factor activities (defined by the GO “Molecular Function” ontology).
(D & F) Validation of array data by RT-qPCR. (G) Expression patterns of late EPC transcription factors during in vitro cultivation.
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time. In this study we have identified by mRNA profiling
various novel surface markers for early and late EPCs
(Figure 2). It is now possible to use new biomarkers
disclosed here, together with AC133/CD34/KDR and
culture assays, to direct isolate and count early and late
EPCs from cord blood and peripheral blood (PB). The
later point is of clinical importance since EPC number in
peripheral blood has been found to correlate with disease
prognosis.
It has been hypothesized that eEPC principally promote
angiogenesis in a paracrine manner, while late EPC directly
participate in endothelial tubulogenesis and may therefore
provide the building blocks for neovascularization [3,5,18].
Paracrine factors secreted by eEPC can further prevent
oxidative stress-induced apoptosis of mature endothelial
cells [4,19]. HGF, VEGF, IL2, IL8, G-CSF and GM-CSF are
known angiogenic factors that are secreted by eEPCs
[18,19]. In addition to HGF, we discovered that eEPCs also
secret abundant pro-angiogenic factors including CCL3/4/
18, CXCL12/16, EBI3, IGF1 and IL10 (Figure 3). CCL3,
CCL18, CXCL12/SDF-1, CXCL16, IGF1 and IL10 have
been linked to pro-angiogenesis and/or coronary artery
diseases [25-27]. These findings allow the development of
novel angiogenic therapies that rely on the secreted growth
factors delivered to sites of ischemia. Combined thera-
peutic angiogenesis, including the provision of local angio-
genic factors and cultured eEPCs is another approach to
be considered.
There are challenges to harnessing EPCs for cell ther-
apy. One of these is their rarity (0.01-0.02 per 106 mono-
nuclear cells), which makes EPC isolation challenging.
Optimization of the cultivation and amplification of EPCs
is therefore required before these cells may be appropri-
ately investigated for use in clinical therapies. It has been
shown that eEPCs do not proliferate significantly in vitro
[18]. Although late EPCs express abundant proliferation
genes (Figure 3B) and can be amplified in vitro, the
delayed outgrowth of late EPCs from culture limits their
application in cases of acute ischemia (such as stroke)
where there may be a limited time window for clinical
benefit. Furthermore, maturation and additional differen-
tiation occurs during propagation (Figure 4A). Late EPCs
can be cultured to up to 15 passages in most cases (not
shown), and the expression levels of key transcription
factors (such as GATA6 and IRF6; Figure 4G) begin toalter in late EPCs during in vitro propagation. The unique
expression pattern of the various transcription factors
identified in this study suggests that they have important
roles in EPC stemness and EC maturation. Controlling the
levels of precursor transcription factors by gene transduc-
tion or by developing new late EPC culture cocktails
should eventually benefit the clinical applications of EPCs.
Conclusions
Our results combine mRNA profiling and gene set ana-
lysis in order to decipher the RNA expression situation at
the various different stages of EPC. With this information,
it will be possible to discover numerous molecular targets
that are crucial for EPC differentiation and functioning.
Although new research directions and hypotheses are pro-
vided by this work, careful functional studies of the genes
in the context of in vitro and in vivo models of angiogen-
esis are still necessary to further support the clinical rele-
vance of these exciting findings. We envision that our
report will serve as a resource for future studies that aim
to improve understanding of the various regulatory ultim-
ately modulating EPC and EC activities.
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Additional file 2: Figure S1. PCA derived from all of the probesets.
Additional file 3: Figure S2. Distribution of late EPC genes in Wnt
signaling pathway. Late genes are labeled with red stars.
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enriched with genes involved in cardiovascularsystem function (A), while
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